General
Preferred name
HALOPERIDOL DECANOATE
Synonyms
KD 16 ()
KD-136 ()
KD 136 ()
Neoperidole ()
Haldol ()
Halomonth ()
R-13,672 ()
R-13672 ()
Haldol Dec ()
P&D ID
PD071740
CAS
74050-97-8
Tags
available
prodrug
drug
Approved by
FDA
First approval
1986
Drug Status
approved
Max Phase
4.0
Drug indication
delirium
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION
Haloperidol decanoate shows antipsychotic activity. Haloperidol decanoate can be used in schizophrenia and schizoaffective disorder research[1].
PRICE
76
DESCRIPTION
Haloperidol decanoate (KD 16) is a typical antipsychotic agent utilized as maintenance treatment for schizophrenia and mood disorders formulated as an ester for intramuscular injection.
(TargetMol Bioactive Compound Library)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Compound Sets
11
ChEMBL Approved Drugs
ChEMBL Drugs
Drug Repurposing Hub
DrugCentral
DrugCentral Approved Drugs
DrugMatrix
LSP-MoA library (Laboratory of Systems Pharmacology)
MedChem Express Bioactive Compound Library
ReFrame library
Selleckchem Bioactive Compound Library
TargetMol Bioactive Compound Library
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
25
Molecular Weight
529.28
Hydrogen Bond Acceptors
4
Hydrogen Bond Donors
0
Rotatable Bonds
15
Ring Count
3
Aromatic Ring Count
2
cLogP
8.12
TPSA
46.61
Fraction CSP3
0.55
Chiral centers
0.0
Largest ring
6.0
QED
0.13
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Indication
schizophrenia
Target
DRD2, DRD3, DRD4, HTR2A
D2R
COX
Dopamine Receptor
NO Synthase
MOA
psychoactive drug
Pathway
GPCR/G protein
Immunology/Inflammation
Neuronal Signaling
Source data
